1. Targeting of BMI-1 with PTC-209 shows potent anti-myeloma activity and impairs the tumour microenvironment
   Arnold Bolomsky et al, 2016, Journal of Hematology & Oncology CrossRef
2. The combination of the tubulin binding small molecule PTC596 and proteasome inhibitors suppresses the growth of myeloma cells
   Yurie Nagai et al, 2021, Scientific Reports CrossRef
3. The polycomb group protein BMI-1 inhibitor PTC-209 is a potent anti-myeloma agent alone or in combination with epigenetic inhibitors targeting EZH2 and the BET bromodomains
   Mohammad Alzrigat et al, 2017, Oncotarget CrossRef
4. The anti‐mitotic agents PTC‐028 and PTC596 display potent activity in pre‐clinical models of multiple myeloma but challenge the role of BMI‐1 as an essential tumour gene
   Arnold Bolomsky et al, 2020, British Journal of Haematology CrossRef
5. miR-203 inhibits cell growth and regulates G1/S transition by targeting Bmi-1 in myeloma cells
   Shun-Quan Wu et al, 2016, Molecular Medicine Reports CrossRef
6. Role of Polycomb Complexes in Normal and Malignant Plasma Cells
   Emmanuel Varlet et al, 2020, International Journal of Molecular Sciences CrossRef
7. Mitogen-activated protein kinase kinase 3 induces cell cycle arrest via p38 activation mediated Bmi-1 downregulation in hepatocellular carcinoma
   LIN WANG et al, 2016, Molecular Medicine Reports CrossRef
8. Polycomb Group (PcG) Proteins and Human Cancers: Multifaceted Functions and Therapeutic Implications
   Wei Wang et al, 2015, Medicinal Research Reviews CrossRef
9. Genome Instability in Multiple Myeloma: Facts and Factors
   Anna Y. Aksenova et al, 2021, Cancers CrossRef